Literature DB >> 26886527

Epigenetic Modulators and the New Immunotherapies.

Anthony E Dear1.   

Abstract

Mesh：

Substances：

Year:  2016        PMID： 26886527     DOI： 10.1056/NEJMcibr1514673

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  25 in total

Review 1.  Integrative Pharmacology: Advancing Development of Effective Immunotherapies.

Authors:  Mohammad Tabrizi; Daping Zhang; Vaishnavi Ganti; Glareh Azadi
Journal:  AAPS J       Date:  2018-04-27       Impact factor: 4.009

Review 2.  Hypomethylating Agents as a Therapy for AML.

Authors:  Claude Gardin; Hervé Dombret
Journal:  Curr Hematol Malig Rep       Date:  2017-02       Impact factor: 3.952

Review 3.  DNA methylation as a transcriptional regulator of the immune system.

Authors:  Luisa Morales-Nebreda; Fred S McLafferty; Benjamin D Singer
Journal:  Transl Res       Date:  2018-08-09       Impact factor: 7.012

Review 4.  Immune Checkpoint Inhibitors in Acute Myeloid Leukemia: Novel Combinations and Therapeutic Targets.

Authors:  Maximilian Stahl; Aaron D Goldberg
Journal:  Curr Oncol Rep       Date:  2019-03-23       Impact factor: 5.075

5.  Immunotherapy for acute myeloid leukemia: from allogeneic stem cell transplant to novel therapeutics.

Authors:  David A Knorr; Aaron D Goldberg; Eytan M Stein; Martin S Tallman
Journal:  Leuk Lymphoma       Date:  2019-07-23

6.  Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors.

Authors:  Muhammad S Beg; Andrew J Brenner; Jasgit Sachdev; Mitesh Borad; Yoon-Koo Kang; Jay Stoudemire; Susan Smith; Andreas G Bader; Sinil Kim; David S Hong
Journal:  Invest New Drugs       Date:  2016-12-05       Impact factor: 3.850

7.  Biopolymers codelivering engineered T cells and STING agonists can eliminate heterogeneous tumors.

Authors:  Tyrel T Smith; Howell F Moffett; Sirkka B Stephan; Cary F Opel; Amy G Dumigan; Xiuyun Jiang; Venu G Pillarisetty; Smitha P S Pillai; K Dane Wittrup; Matthias T Stephan
Journal:  J Clin Invest       Date:  2017-04-24       Impact factor: 14.808

Review 8.  Targeting the cancer epigenome for therapy.

Authors:  Peter A Jones; Jean-Pierre J Issa; Stephen Baylin
Journal:  Nat Rev Genet       Date:  2016-09-15       Impact factor: 53.242

9.  Methylomes of renal cell lines and tumors or metastases differ significantly with impact on pharmacogenes.

Authors:  Stefan Winter; Pascale Fisel; Florian Büttner; Steffen Rausch; Debora D'Amico; Jörg Hennenlotter; Stephan Kruck; Anne T Nies; Arnulf Stenzl; Kerstin Junker; Marcus Scharpf; Ute Hofmann; Heiko van der Kuip; Falko Fend; German Ott; Abbas Agaimy; Arndt Hartmann; Jens Bedke; Matthias Schwab; Elke Schaeffeler
Journal:  Sci Rep       Date:  2016-07-20       Impact factor: 4.379

10.  A DNA Hypomethylating Drug Alters the Tumor Microenvironment and Improves the Effectiveness of Immune Checkpoint Inhibitors in a Mouse Model of Pancreatic Cancer.

Authors:  Tamas A Gonda; Jarwei Fang; Martha Salas; Catherine Do; Emily Hsu; Anna Zhukovskaya; Ariel Siegel; Ryota Takahashi; Zoila A Lopez-Bujanda; Charles G Drake; Gulam A Manji; Timothy C Wang; Kenneth P Olive; Benjamin Tycko
Journal:  Cancer Res       Date:  2020-08-14       Impact factor: 13.312
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.